Have any questions?
+44 1234 567 890
FIX CHAGAS Study Reaches 50% Patient Enrollment
Successful collaboration between the InCor Heart Center and i2medi—the LATAM market access expert
InCor reports that 50% of the planned patients have been enrolled in the randomized FIX-CHAGAS study on CCM in Chagas-related cardiomyopathy.
i2medi initiated the project led by the InCor in Sao Paulo and is supporting its implementation in Brazil—from study management to the expert network.
Another example of the way i2medi is positioning itself as the leading business development agency and CRO partner for medtech companies in Latin America.